Although fosfomycin is currently approved for treating urinary tract infections, it is increasingly being used as salvage therapy for various infectious syndromes outside the urinary tract. This systematic review evaluates clinical and microbiological cure rates in patients with bacterial infections not restricted to the urinary tract where fosfomycin was used off-label. C-Path’s Executive Director of the CDRC Marco Schito was a c0-author on this publication. You can read it in full in Le Infezioni in Medicina, here.
